Second, it will stimulate a search for the specific target genes abnormally regulated in nasal and eye development, although this may be tricky-both because of species specificity and because the malformation may originate during only a very brief window of embryonic development of the nasal placode and optic vesicle. Finally, knowledge of these mutations will prove invaluable as efforts continue to understand the role of the GHKL ATPase and (yet to be delineated) interacting partners of SMCHD1, possibly leading to new therapeutic approaches for FSHD.
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loss-of-function or (weak) dominant-negative activity 4, 5 (Fig. 1c) . Of note, mixed loss-and gain-of-function mutations in the same proteincoding gene are not without precedent, for example, when biochemical activation is counterbalanced by protein misfolding or trafficking defects 15 ; such instability has indeed been demonstrated for one GHKL ATPase mutation in FSHD2 (ref. 9). Moreover, ATPase activation may cause release of SMCHD1 from chromatin, acting in the same direction as loss of function 7 . How does this work move the field forward? First, it provides individuals affected by BAMS with a molecular diagnosis to enable proper genetic counseling; further substantial efforts will be needed to identify additional factors modulating the severity of the phenotype.
swi/snF complex in cancer

Chao Lu & C David Allis
Four studies in this issue report new mechanisms underlying the function of the chromatin remodeling swi/snF complex in controlling gene expression and suppressing tumor development, providing valuable insights into the treatment of cancers harboring mutations in genes encoding swi/snF complex subunits. The SWI/SNF complex (also known as the BAF complex) was originally described in yeast as the protein complex critical for cellular responses to mating-type switching (SWI) or sucrose fermentation (SNF) 1, 2 . Constituting a large (~2-MDa) complex containing more than 15 subunits, the SWI/SNF complex activates gene expression, which is thought to result from its capacity to remodel and evict nucleosomes at gene promoters 3 . Recently, the SWI/SNF complex has been linked to a number of human diseases, most notably, cancer. Mutations, translocations and deletions involving various subunits of the SWI/ SNF complex were found in ~20% of human tumors, making the complex one of the most commonly affected in cancer 4 . In this issue, four research articles offer novel insights into the mechanisms by which alterations of the SWI/ SNF complex lead to defective complex assembly and recruitment, abnormal gene silencing and tumor development [5] [6] [7] [8] . Importantly, these mechanisms help explain the preclinical efficacies of several therapeutic approaches developed to target SWI/SNF-mutated tumors.
Remodeling enhancers
Loss of SMARCB1 (also known as SNF5 or BAF47) is the defining molecular feature of childhood malignant rhabdoid tumors. To investigate the impact of SMARCB1 inactivation on SWI/SNF complex assembly and targeting, Charles Roberts, Bradley Bernstein, Peter Park and colleagues 5 examined the genomewide localization of the SWI/SNF complex in wild-type and SMARCB1-deficient rhabdoid tumors and cell lines. They found that a substantial portion of SWI/SNF complexes, in addition to being localized to promoters, were recruited to enhancers and so-called super-enhancers (clusters of active enhancers) in wild-type cells. Interestingly, loss of SMARCB1 caused disassembly of most SWI/SNF complexes at promoters and typical enhancers, but only minimally affected super-enhancer-associated complexes. The authors propose that, because typical enhancers regulate the expression of genes involved in lineage specification whereas superenhancers are linked to genes maintaining cell identity, the redistribution of SWI/SNF complexes may impair the potential of SMARCB1-deficient cells to differentiate while maintaining their self-renewal, survival and proliferation capacities, thus promoting tumorigenesis.
Another study from the Roberts laboratory focused on cancer-associated ARID1A inactivation. The authors found that genetic knockout of Arid1a in mouse colon tissues resulted in development of invasive colon adenocarcinomas resembling human colorectal cancers. Tumor growth was independent of APC inactivation and represents a new mouse model for the study of colon cancer. Similarly, the authors observed that the majority of SWI/ SNF complexes, particularly those at enhancers, were compromised upon ARID1A loss, which in turn caused marked deregulation of developmental gene expression. The remaining SWI/SNF complexes were maintained by the ARID1B isoform and seemed to be critical for tumor survival, as depletion of ARID1B was selectively toxic to ARID1A-deficient cells, consistent with previous findings 9 .
Taken together, these two studies identify a previously underappreciated role for the SWI/SNF complex at gene enhancers and super-enhancers. They also provide potential explanations for why SWI/SNF mutations in cancer, particularly those affecting the regulatory subunits such as ARID1A, ARID1B and SMARCB1, exhibit a high degree of tissue specificity and why SWI/SNF-mutated tumors are hypersensitive to the inhibition of residual complex activity 9, 10 .
'SWIng' Polycomb complexes off chromatin
What is the molecular connection between abnormal SWI/SNF activity and deregulatedWhile these studies highlight exciting new biology of SWI/SNF complex (Fig. 1) , they also raise several interesting concepts inspiring future studies. In addition to the well-characterized intercellular heterogeneity of the SWI/SNF complex, it now seems plausible that intracellular heterogeneity of this complex also exists and may be functionally important. Proteomic and epigenomic analyses are required to determine whether variants of the SWI/SNF complex, such as SMARCB1-null or ARID1B-containing complexes, localize to distinct genomic regions (for example, typical enhancers versus super-enhancers) and differ in their abilities to remodel nucleosomes and/or oppose Polycomb-mediated silencing. Notably, several subunits of the SWI/SNF complex possess putative DNA-binding domains and 'reader' domains for chromatin modifications, which may underline the potential variant-specific chromatin recruitment mechanism. Further characterization of SWI/SNF-mediated PRC1 chromatin eviction using purified proteins and customized nucleosome arrays will be critical to understand the biochemical mechanisms, especially in relation to the well-known nucleosome-remodeling activity of this complex. Finally, given the conserved genetic antagonism between SWI/SNF and PRC complexes, whether inhibiting the SWI/ SNF complex could effectively treat tumors carrying inactivating mutations or deletions of Polycomb complex subunits should be explored 14 . Because of the high prevalence of SWI/SNF and Polycomb complex mutations in cancer, a better understanding of the interplay between these complexes will have far-reaching implications for clinical strategies moving forward. stimulation of ATP hydrolysis, consistent with a model whereby the ATPase activity of SWI/ SNF directly releases PRC1.
To study the dynamic mechanisms underlying SWI/SNF and Polycomb complex opposition in vivo, Kadoch et al. 8 developed a novel system to chemically induce local recruitment of SWI/ SNF complex in a rapid and reversible manner. They found that loss of PRC1 from chromatin occurred within minutes of SWI/SNF complex recruitment. Furthermore, SWI/SNF-mediated PRC1 eviction was reversible, dependent on its ATPase activity, and independent of transcription, replication, nucleosome turnover and changes in chromatin accessibility. Removal of the tumor suppressor SMARCB1 from the SWI/SNF complex resulted in reduced ability to oppose PRC1, whereas the oncogenic SWI/SNF complex containing the SS18-SSX1 fusion protein, which is found in 100% of synovial sarcomas, displayed enhanced chromatin occupancy and PRC1 eviction. Collectively, these results suggest that, in addition to the commonly held belief, Polycomb complexes are critical non-nucleosomal substrates of SWI/SNF and provide strong rationale for targeting Polycomb-mediated gene silencing, for example, through pharmacological inhibition of PRC1, as a therapeutic strategy for SWI/ SNF-inactivated tumors. (refs. 12,13) . The biochemical mechanism underlying such opposition, however, has remained elusive. Two studies from the laboratories of Jerry Crabtree and Cigall Kadoch have provided compelling evidence in support of an unexpected function of the SWI/SNF complex in direct eviction of PRC1 from chromatin 7, 8 . Stanton et al. 7 found that, upon deletion of the Smarca4 gene encoding the ATPase subunit in mouse embryonic stem cells, there was a genome-wide increase in the localization of PRC1 and PRC2, as well as enrichment of trimethylation of histone H3 at lysine 27 (H3K27me3). The enhanced Polycomb silencing effects could be reversed by re-expressing wild-type SMARCA4 but not the cancer-associated ATPase-mutant SMARCA4. Importantly, coimmunoprecipitation experiments identified a chromatin-independent interaction between the SWI/SNF complex and PRC1 complex components, which could be disrupted by 
